Comparison of 2 drugs in general anaesthesia for their side effects , time taken for recovery from neuromuscular paralysis

Comparison of Sugammadex vs Neostigmine in Reversal of Vecuronium induced Neuromuscular blockade - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/10/074937

Enrollment

Registered

2024-10-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K800- Calculus of gallbladder with acutecholecystitis Health Condition 2: C509- Malignant neoplasm of breast of unspecified site Health Condition 3: E069- Thyroiditis, unspecified Health Condition 4: K429- Umbilical hernia without obstruction or gangrene

Interventions

Intervention1: General Anaesthesia: Injecting reversal agent at the end of surgery for neuromuscular recovery under 2 hours Control Intervention1: Sugammadex vs Neostigmine: Comparison of IV Sugammade

Eligibility

Inclusion criteria

Inclusion criteria: Patients posted for elective surgery under General anaesthesia. Stable medical condition(ASA grade l and II): Ability to provide informed consent .

Exclusion criteria

Exclusion criteria: Allergy or contraindication to Sugammadex ,Neostigmine. Unstable medical conditions (ASA grade III and IV) Recent exposure to neuromuscular blocking agents: Pregnancy or breastfeeding. Patients with Neuromuscular disorders Inability to provide informed consent. Participation in other studies

Design outcomes

Primary

Measure	Time frame
To assess the time taken for recovery of neuromuscular function (time to train-of-four ratio = 0.9) after administration of Sugammadex versus Neostigmine. To compare the quality of neuromuscular recovery between Sugammadex and Neostigmine, including parameters such as the return of spontaneous ventilation, muscle strength, and reversal completeness.Timepoint: At baseline	—

Secondary

Measure	Time frame
To assess the time to extubation after the administration of Sugammadex versus Neostigmine. To evaluate the incidence of adverse events associated with the use of Sugammadex and Neostigmine, including but not limited to respiratory complications, cardiovascular events, and allergic reactions.Timepoint: 7 days	—

Countries

India

Contacts

Public ContactDR Anita Pareek

Sardar Patel Medical College, Bikaner

dranitapareek23@gmail.com9828101281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026